Literature DB >> 9655849

Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin.

K Takeuchi1, H Ukawa, A Konaka, M Kitamura, Y Sugawa.   

Abstract

The effects of a nitric oxide (NO)-releasing derivative of aspirin, NCX-4016, on gastric functional and ulcerogenic responses in rat stomachs were examined in comparison with those of aspirin. Topical application of aspirin (80 mM) to the stomach markedly decreased transmucosal potential difference and slightly increased luminal pH (acid back-diffusion) with minimal effect on mucosal blood flow, whereas NCX-4016 caused a marked increase in mucosal blood flow with no effect on potential difference and pH. Aspirin itself was ulcerogenic, causing damage in the mucosa when administered p.o., and it markedly potentiated gastric ulcerogenic response to hypothermic stress (28 degrees C-30 degrees C) with no effect on acid secretion when given s.c. NCX-4016, however, was not ulcerogenic by itself, did not modify the ulcerogenic response to stress and even showed a dose-dependent protection against HCl/ethanol-induced gastric lesions. When NCX-4016 was given intragastrically to pylorus-ligated rats, a large amount of NO was detected in both gastric contents and serum. NCX-4016 administered either p.o. or s.c. produced an equipotent inhibition of mucosal PGE2 generation in the stomach, as compared with aspirin. In addition, both aspirin and NCX-4016 suppressed carrageenan-induced rat paw edema. These results suggest that, unlike aspirin, the NO-releasing derivative of aspirin NCX-4016 neither had a topical irritating action on the stomach nor exerted a worsening effect on gastric ulcerogenic response to stress, but rather provided gastric protection against ethanol, despite inhibiting cyclo-oxygenase activity and showing anti-inflammatory action much as aspirin does. NCX-4016, probably by releasing NO, exerted protective effects that counteracted the potential damaging effects of cyclo-oxygenase inhibition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655849

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Preconditioning stress prevents cold restraint stress-induced gastric lesions in rats: roles of COX-1, COX-2, and PLA2.

Authors:  Akiko Tanaka; Ryo Hatazawa; Yuka Takahira; Nahoko Izumi; Ludmila Filaretova; Koji Takeuchi
Journal:  Dig Dis Sci       Date:  2007-01-17       Impact factor: 3.199

Review 2.  Nitric oxide-releasing NSAIDs: a review of their current status.

Authors:  S Fiorucci; E Antonelli; J L Burgaud; A Morelli
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.

Authors:  R La Corte; M Caselli; G Castellino; G Bajocchi; F Trotta
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

4.  Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.

Authors:  P A Gray; T D Warner; I Vojnovic; P Del Soldato; A Parikh; G K Scadding; J A Mitchell
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

5.  Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats.

Authors:  M N Muscará; F Lovren; W McKnight; M Dicay; P del Soldato ; C R Triggle; J L Wallace
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

6.  Vasorelaxant effect of nitric oxide releasing steroidal and nonsteroidal anti-inflammatory drugs.

Authors:  J Keeble; O A Al-Swayeh; P K Moore
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

7.  Lack of gastric toxicity of nitric oxide-releasing indomethacin, NCX-530, in experimental animals.

Authors:  K Takeuchi; H Mizoguchi; H Araki; Y Komoike; K Suzuki
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

8.  Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis.

Authors:  S Kato; K Suzuki; H Ukawa; Y Komoike; K Takeuchi
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

Review 9.  Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs.

Authors:  J E Keeble; P K Moore
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

10.  NCX 4016, a nitric oxide-releasing aspirin, modulates adrenergic vasoconstriction in the perfused rat tail artery.

Authors:  Giuseppe Rossoni; Barbara Manfredi; Piero Del Soldato; Ferruccio Berti
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.